Weight-Loss Drug Effects and Upcoming Generic Semaglutide Launch in India

Injectable GLP-1 drugs like semaglutide and tirzepatide have significantly advanced obesity and diabetes treatment by reducing appetite and improving metabolic control. However, research from the University of Oxford shows that many patients regain a substantial portion of lost weight within a year after stopping these medications, highlighting obesity's chronic nature. Meanwhile, India is preparing for the introduction of over two dozen generic semaglutide versions following the drug's patent expiration, which may increase accessibility by lowering costs in the expanding metabolic treatment market.